Lv1
20 积分 2022-08-03 加入
RIPTACs expand anticancer target space
5天前
已完结
Tumor targeted radionuclide-nanomedicine for clinical translation: From carrier innovation to precision therapy
25天前
已完结
CD56 on immune and tumor cells: what is known and beyond?
3个月前
已完结
From KRAS G12D to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design
3个月前
已完结
Combinatorial strategies to target RAS-driven cancers
5个月前
已完结
Immune agonist antibodies face critical test
5个月前
已完结
Therapeutic Fusion Proteins
8个月前
已完结
Targeted protein degrader development for cancer: advances, challenges, and opportunities
8个月前
已完结
Vaccine development: Current trends and technologies
8个月前
已完结
Therapeutic Fusion Proteins
8个月前
已完结
皖公网安备34019202002308
